Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Evolus
< Previous
1
2
Next >
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
September 06, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
July 31, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Hold Investor Day on September 12, 2024
July 31, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
July 25, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Second Quarter Financial Results on July 31, 2024
July 17, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Appointment of Albert G. White III to Board of Directors
July 01, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
June 24, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright